Shots:
- Sanofi and J&J have discontinued the P-III (E.mbrace) study of ExPEC9V after IDMC interim analysis due to insufficient efficacy against extraintestinal pathogenic E. coli , leading to a $250M impairment charge before tax
- The P-III trial assessed single dose of ExPEC9V (IM) vs PBO in adults (≥60yrs.) with UTI history in past 2yrs. to prevent invasive E. coli diseases incl. sepsis & bacteremia
- Sanofi and J&J jointly developed ExPEC9V under an agreement (Oct 2023), with Sanofi paying $250M upfront with potential development & commercial milestones, while R&D costs were co-funded
Ref: Sanofi | Image: Sanofi and J&J
Related News:- Sanofi Receives China’s NMPA Approval for Sarclisa + SoC VRd to Treat Newly Diagnosed Multiple Myeloma (NDMM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
